Fetuin-A has been proposed as a potential tumor marker in specific malign neoplasia, including in pancreatic and breast cancer, and a decrease in Fetuin-A levels in serum from patients with chronic lymphoblastic leukemia (CLL) compared to those of healthy controls has been reported [38]. This evidence concerns the gene AHSG and B-cell chronic lymphocytic leukemia.